| Name | Adapalene |
| Description | Adapalene (CD271) is a dual RAR and RXR agonist, utilized in the treatment of skin conditions. |
| In vitro | In rhino mice, Adapalene reduces the quantity of comedonal melanin in the epidermis and increases epidermal thickness. Within both normal skin and acne explants, Adapalene decreases the expression of TLR-2 (TLR-2) and IL-10 (IL-10). By upregulating CD1d expression and downregulating the IL-10 expression in keratinocytes, Adapalene modulates the epidermal immune system. This action enhances the interaction between dendritic cells and T lymphocytes, augmenting antimicrobial activity against Propionibacterium acnes. |
| In vivo | In colorectal cancer cell lines CC-531, HT-29, and LOVO, as well as in human foreskin fibroblasts, Adapalene induces caspase-3 activity in tumor cells, inhibits DNA synthesis in a time- and dose-dependent manner, and triggers apoptosis. |
| Storage | keep away from direct sunlight,store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 1 mg/ml, Sonication is recommended.
|
| Keywords | RAR/RXR | GOT1 | acne | RARα | Adapalene | Autophagy | Retinoid X receptors | CD 271 | Inhibitor | RARγ | tumor | retinoid | Apoptosis | RAR | CD-271 | Retinoic acid receptors | RARβ | inhibit |
| Inhibitors Related | Stavudine | Sodium 4-phenylbutyrate | L-Ascorbic acid | Hydroxychloroquine | Guanidine hydrochloride | Taurine | Tributyrin | Paeonol | Naringin | Salicylic acid | Gefitinib | Oleic acid |
| Related Compound Libraries | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | NO PAINS Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
